Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients

Sari L Reisner, Madeline B Deutsch, Sarah M Peitzmeier, Jaclyn M White Hughto, Timothy P Cavanaugh, Dana J Pardee, Sarah A McLean, Lori A Panther, Marcy Gelman, Matthew J Mimiaga, Jennifer E Potter, Sari L Reisner, Madeline B Deutsch, Sarah M Peitzmeier, Jaclyn M White Hughto, Timothy P Cavanaugh, Dana J Pardee, Sarah A McLean, Lori A Panther, Marcy Gelman, Matthew J Mimiaga, Jennifer E Potter

Abstract

Background: High-risk human papillomavirus (hrHPV) causes virtually all cervical cancers. Trans masculine (TM) people (those assigned female at birth who identify with a gender other than female) have low uptake of conventional cervical cancer screening. Self-collected hrHPV DNA testing has high levels of acceptability among cisgender (non-transgender) females and may support increased cervical cancer screening uptake in TM individuals.

Objective: To assess the test performance and acceptability of self-collected vaginal specimens in comparison to provider-collected cervical swabs for hrHPV DNA detection in TM individuals ages 21-64 years.

Methods: Between March 2015-September 2016, 150 TM participants with a cervix (mean age = 27.5 years; SD = 5.7) completed a one-time study visit comprised of a self-report survey, self-collected vaginal HPV DNA swab, clinician-administered cervical HPV swab, and brief interview on acceptability of clinical procedures. Participants were randomized to complete either self- or provider-collection first to minimize ordering effects. Self- and provider-collected samples were tested for 13 hrHPV DNA types using a DNA Hybridization Assay. The primary outcome variable was the concordance (kappa statistic) and performance (sensitivity, specificity) of self-collected vaginal HPV DNA specimens versus provider-collected cervical HPV swabs as the gold standard.

Results: Of the 131 participants completing both the self- and provider-collected HPV tests, 21 cases of hrHPV were detected by the provider cervical swab (gold standard; 16.0% hrHPV prevalence); 15 of these cases were accurately detected by the self-collected vaginal swab (71.4% concordance) (Kappa = 0.75, 95% Confidence Interval [CI]: 0.59, 0.92; p<0.001). Compared to the provider-collected cervical hrHPV DNA sample (gold standard), the self-collected vaginal hrHPV DNA test demonstrated a sensitivity of 71.4% (95% CI: 0.52, 0.91; p = 0.0495) and specificity of 98.2% (95% CI: 0.96, 1.00; p<0.0001). Over 90% of participants endorsed a preference for the self-collected vaginal swab over provider-collected cervical swab.

Conclusion: Self-collected vaginal swabs are highly acceptable to TM as a means to test for hrHPV DNA. Test performance of this self-collection method for hrHPV detection in TM is consistent with previous studies in cisgender females. Self-collected vaginal swab testing for hrHPV DNA represents a reasonable and patient-centered strategy for primary cervical cancer screening in TM patients unwilling to undergo provider collection of specimens via speculum exam.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report 2016. Available from: Available at: .
    1. Centers for Disease Control and Prevention (CDC). Incidence, prevalence, and cost of sexually transmitted infections in the United States Atlanta, GA: CDC; 2013 [cited 2017 Jan 15]. Available from: .
    1. Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, et al. Human Papillomavirus-Associated Cancers—United States, 2008–2012. MMWR Morb Mortal Wkly Rep. 2016;65(26):661–6. Epub 2016/07/09. doi: .
    1. Benard VB, Thomas CC, King J, Massetti GM, Doria-Rose VP, Saraiya M. Vital signs: cervical cancer incidence, mortality, and screening—United States, 2007–2012. MMWR Morb Mortal Wkly Rep. 2014;63(44):1004–9. Epub 2014/11/07. mm6344a5 [pii]. .
    1. Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156(12):880–91, W312. Epub 2012/06/20. doi: [pii]. .
    1. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516–42. Epub 2012/03/21. doi: [pii]. .
    1. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121(4):829–46. Epub 2013/05/03. doi: [pii]. .
    1. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136(2):178–82. Epub 2015/01/13. doi: [pii]. .
    1. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015;125(2):330–7. Epub 2015/01/09. doi: .
    1. U.S. Preventive Services Task Force (USPSTF). Final Update Summary: Cervical Cancer: Screening. U.S. Preventive Services Task Force Rockville, MD: U.S. Preventive Services Taks Force Program Office; 2016 [cited 2017 May 15]. Available from: .
    1. Practice Bulletin No. 157: Cervical Cancer Screening and Prevention. Obstet Gynecol. 2016;127(1):e1–e20. Epub 2015/12/24. doi: [pii]. .
    1. Committee Opinion no. 512: health care for transgender individuals. Obstet Gynecol. 2011;118(6):1454–8. Epub 2011/11/23. doi: [pii]. .
    1. Peitzmeier SM, Khullar K, Reisner SL, Potter J. Pap test use is lower among female-to-male patients than non-transgender women. Am J Prev Med. 2014;47(6):808–12. Epub 2014/12/03. doi: .
    1. Reisner SL, Hughto JM, Dunham EE, Heflin KJ, Begenyi JB, Coffey-Esquivel J, et al. Legal Protections in Public Accommodations Settings: A Critical Public Health Issue for Transgender and Gender-Nonconforming People. Milbank Q. 2015;93(3):484–515. Epub 2015/07/30. doi: ; PubMed Central PMCID: PMC4567851.
    1. Potter J, Peitzmeier SM, Bernstein I, Reisner SL, Alizaga NM, Agenor M, et al. Cervical Cancer Screening for Patients on the Female-to-Male Spectrum: a Narrative Review and Guide for Clinicians. J Gen Intern Med. 2015;30(12):1857–64. Epub 2015/07/15. doi: [pii]. ; PubMed Central PMCID: PMC4636588.
    1. Agenor M, Peitzmeier SM, Bernstein IM, McDowell M, Alizaga NM, Reisner SL, et al. Perceptions of cervical cancer risk and screening among transmasculine individuals: patient and provider perspectives. Cult Health Sex. 2016;18(10):1192–206. Epub 2016/05/05. doi: .
    1. Kaufman R. Introduction to Transgender Identity and Health In: Makadon H, Mayer KH, Potter J, Goldhammer H, editors. The Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health. Philadelphia: American College of Physicians; 2008. p. 331–63.
    1. Driak D, Samudovsky M. Could a man be affected with carcinoma of cervix?—The first case of cervical carcinoma in trans-sexual person (FtM)—case report. Acta Medica (Hradec Kralove). 2005;48(1):53–5. .
    1. Feldman JL. Preventive care of the transgendered patient: An evidence-based approach In: Ettner R, Monstrey S, Eyler E, editors. Principles of Transgender Medicine and Surgery. Binghampton, New York: Haworth Press; 2007. p. 33–72.
    1. Kenagy GP. Transgender health: findings from two needs assessment studies in Philadelphia. Health Soc Work. 2005;30(1):19–26. .
    1. O'Hanlan KA, Dibble SL, Young-Spint M. Total laparoscopic hysterectomy for female-to-male transsexuals. Obstet Gynecol. 2007;110(5):1096–101. doi: .
    1. Rachlin K, Green J, Lombardi E. Utilization of health care among female-to-male transgender individuals in the United States. J Homosex. 2008;54(3):243–58. doi: .
    1. van Trotsenburg MAA. Gynecological Aspects of Transgender Healthcare. Int J Transgend. 2009;11:238–46.
    1. Seay J, Ranck A, Weiss R, Salgado C, Fein L, Kobetz E. Understanding Transgender Men's Experiences with and Preferences for Cervical Cancer Screening: A Rapid Assessment Survey. LGBT Health. 2017. Epub 2017/04/20. doi: .
    1. McDowell M, Pardee D, Peitzmeier S, Reisner S, Agénor M, Alizaga N, et al. Cervical cancer screening preferences among trans-masculine individuals: Patient-collected human papillomavirus vaginal swabs versus provider-administered pap tests. LGBT Health. 2017;4(4):252–9. doi:
    1. Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol. 2007;105(2):530–5. Epub 2007/03/06. doi: .
    1. Harper DM, Noll WW, Belloni DR, Cole BF. Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed—biologic concordance and women's preferences. Am J Obstet Gynecol. 2002;186(3):365–73. .
    1. Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. Cmaj. 2000;163(5):513–8. .
    1. Wright TC Jr., Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. Jama. 2000;283(1):81–6. .
    1. Rompalo AM, Gaydos CA, Shah N, Tennant M, Crotchfelt KA, Madico G, et al. Evaluation of use of a single intravaginal swab to detect multiple sexually transmitted infections in active-duty military women. Clin Infect Dis. 2001;33(9):1455–61. Epub 2001/09/25. CID001053 [pii] doi: .
    1. Ogilvie GS, Patrick D.M., Schulzer M., Sellors J.W., Petric M., Chambers K., White R. and FitzGerald J.M. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect. 2005;81(3):207–12. doi:
    1. Dannecker C, Siebert U, Thaler CJ, Kiermeir D, Hepp H, Hillemanns P. Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics. Ann Oncol. 2004;15(6):863–9. Epub 2004/05/21. .
    1. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Jaspars LH, Voorhorst FJ, et al. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol. 2002;55(6):435–9. Epub 2002/05/31. ; PubMed Central PMCID: PMC1769675.
    1. Modibbo F, Iregbu KC, Okuma J, Leeman A, Kasius A, de Koning M, et al. Randomized trial evaluating self-sampling for HPV DNA based tests for cervical cancer screening in Nigeria. Infect Agent Cancer. 2017;12:11 Epub 2017/02/12. doi: [pii]. ; PubMed Central PMCID: PMC5294803.
    1. Arrossi S, Thouyaret L, Herrero R, Campanera A, Magdaleno A, Cuberli M, et al. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. Lancet Glob Health. 2015;3(2):e85–94. Epub 2015/01/27. doi: [pii]. .
    1. Snijders PJ, Verhoef VM, Arbyn M, Ogilvie G, Minozzi S, Banzi R, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer. 2013;132(10):2223–36. Epub 2012/08/22. doi: .
    1. Reisner SL, Deutsch MB, Peitzmeier SM, White Hughto JM, Cavanaugh T, Pardee DJ, et al. Comparing self- and provider-collected swabbing for HPV DNA testing in female-to-male transgender adult patients: a mixed-methods biobehavioral study protocol. BMC Infect Dis. 2017;17(1):444 doi: ; PubMed Central PMCID: PMCPMC5481878.
    1. Reisner SL, Bradford J, Hopwood R, Gonzalez A, Makadon H, Todisco D, et al. Comprehensive transgender healthcare: the gender affirming clinical and public health model of Fenway Health. J Urban Health. 2015;92(3):584–92. Epub 2015/03/18. doi: ; PubMed Central PMCID: PMC4456472.
    1. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. Jama. 2002;287(16):2114–9. .
    1. Trottier H, Mahmud SM, Lindsay L, Jenkins D, Quint W, Wieting SL, et al. Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev. 2009;18(3):854–62. Epub 2009/02/19. doi: [pii]. .
    1. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):259–174. doi:
    1. Breslow NE, Day NE. Statistical Methods in Cancer Research. Volume 1—The analysis of case-control studies. Lyon: International Agency for Research on Cancer; 1980.
    1. Peitzmeier SM, RS L, H P, Potter J. Female-to-male transgender patients have high prevalence of unsatisfactory Paps compared to non-transgender females: Implications for cervical cancer screening. J Gen Intern Med. 2014. Epub Jan 15 2014.
    1. Strauss A, Corbin J. Grounded theory in practice. Thousand Oaks, CA: Sage; 1997.
    1. SocioCultural Research Consultants L. Dedoose Software Los Angeles, CA: SocioCultural Research Consultants, LLC; 2017. p. Web application for managing, analyzing, and presenting qualitative and mixed method research data.
    1. Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer. 2008;98(10):1704–9. Epub 2008/04/09. doi: [pii]. ; PubMed Central PMCID: PMC2391119.
    1. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813–9. Epub 2007/03/01. 297/8/813 [pii] doi: .
    1. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–4. Epub 2014/10/10. doi: [pii]. .
    1. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003–2006. J Infect Dis. 2011;204(4):566–73. Epub 2011/07/28. doi: [pii]. .
    1. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147–72. Epub 2012/03/17. doi: ; PubMed Central PMCID: PMC3801360.
    1. Saslow D, Andrews KS, Manassaram-Baptiste D, Loomer L, Lam KE, Fisher-Borne M, et al. Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. CA Cancer J Clin. 2016;66(5):375–85. Epub 2016/07/20. doi: .
    1. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189–97. Epub 2015/01/13. doi: [pii]. .
    1. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–32. Epub 2013/11/07. doi: [pii]. .
    1. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754 Epub 2008/10/15. doi: [pii]. ; PubMed Central PMCID: PMC2658827.
    1. Malila N, Leinonen M, Kotaniemi-Talonen L, Laurila P, Tarkkanen J, Hakama M. The HPV test has similar sensitivity but more overdiagnosis than the Pap test—a randomised health services study on cervical cancer screening in Finland. Int J Cancer. 2013;132(9):2141–7. Epub 2012/09/19. doi: .
    1. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer. 2012;130(3):602–10. Epub 2011/03/15. doi: .
    1. Castle PE, Schiffman M, Glass AG, Rush BB, Scott DR, Wacholder S, et al. Human papillomavirus prevalence in women who have and have not undergone hysterectomies. J Infect Dis. 2006;194(12):1702–5. Epub 2006/11/17. JID36890 [pii] doi: .
    1. Garcia F, Barker B, Santos C, Brown EM, Nuno T, Giuliano A, et al. Cross-sectional study of patient- and physician-collected cervical cytology and human papillomavirus. Obstet Gynecol. 2003;102(2):266–72. Epub 2003/08/09. S0029784403005179 [pii]. .
    1. Khan AM, Sasieni P, Singer A. A prospective double-blind cross-sectional study of the accuracy of the use of dry vaginal tampons for self-sampling of human papillomaviruses. BJOG. 2015;122(3):388–94. Epub 2014/08/05. doi: .
    1. Lack N, West B, Jeffries D, Ekpo G, Morison L, Soutter WP, et al. Comparison of non-invasive sampling methods for detection of HPV in rural African women. Sex Transm Infect. 2005;81(3):239–41. Epub 2005/06/01. 81/3/239 [pii] doi: ; PubMed Central PMCID: PMC1744971.
    1. Gok M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ. 2010;340:c1040 Epub 2010/03/13. doi: [pii]. ; PubMed Central PMCID: PMC2837143.
    1. de Melo Kuil L, Lorenzi AT, Stein MD, Resende JCP, Antoniazzi M, Longatto-Filho A, et al. The Role of Self-Collection by Vaginal Lavage for the Detection of HPV and High-Grade Intraepithelial Neoplasia. Acta Cytol. 2017. Epub 2017/06/01. doi: [pii]. .
    1. Catarino R, Vassilakos P, Bilancioni A, Vanden Eynde M, Meyer-Hamme U, Menoud PA, et al. Randomized Comparison of Two Vaginal Self-Sampling Methods for Human Papillomavirus Detection: Dry Swab versus FTA Cartridge. PLoS One. 2015;10(12):e0143644 Epub 2015/12/03. doi: [pii]. ; PubMed Central PMCID: PMC4668032.
    1. Alidjinou EK, Ebatetou-Ataboho E, Sane F, Moukassa D, Dewilde A, Hober D. Cervical samples dried on filter paper and dried vaginal tampons can be useful to investigate the circulation of high-risk HPV in Congo. J Clin Virol. 2013;57(2):161–4. Epub 2013/03/13. doi: [pii]. .
    1. Holton T, Smith D, Terry M, Madgwick A, Levine T. The effect of lubricant contamination on ThinPrep (Cytyc) cervical cytology liquid-based preparations. Cytopathology. 2008;19(4):236–43. Epub 2007/12/21. CYT525 [pii] doi: .
    1. Peitzmeier SM, Agénor M, Bernstein I, McDowell M, Alizaga NM, Reisner SL, et al. “It can promote an existential crisis”: Factors influencing Pap test acceptability and utilization among transmasculine individuals. Qual Health Res. 2017;(Ahead of Print).
    1. White Hughto JM, Reisner SL, Pachankis JE. Transgender stigma and health: A critical review of stigma determinants, mechanisms, and interventions. Soc Sci Med. 2015;147:222–31. doi:

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa